Harmony Biosciences Holdings, Inc. (HRMY)
US — Healthcare Sector
Automate Your Wheel Strategy on HRMY
With Tiblio's Option Bot, you can configure your own wheel strategy including HRMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HRMY
- Rev/Share 12.9969
- Book/Share 12.5724
- PB 2.7465
- Debt/Equity 0.0243
- CurrentRatio 3.6701
- ROIC 0.1938
- MktCap 1982861079.0
- FreeCF/Share 3.863
- PFCF 8.9564
- PE 12.9579
- Debt/Assets 0.0166
- DivYield 0
- ROE 0.2429
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 1
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | HRMY | Truist | -- | Buy | -- | $48 | July 21, 2025 |
| Resumed | HRMY | Goldman | -- | Neutral | -- | $33 | July 10, 2025 |
| Resumed | HRMY | Oppenheimer | -- | Outperform | -- | $61 | June 2, 2025 |
| Initiation | HRMY | Deutsche Bank | -- | Buy | -- | $55 | Feb. 11, 2025 |
| Initiation | HRMY | H.C. Wainwright | -- | Buy | -- | $75 | Dec. 17, 2024 |
| Resumed | HRMY | Raymond James | -- | Outperform | -- | -- | Oct. 10, 2024 |
| Initiation | HRMY | UBS | -- | Buy | -- | $56 | Sept. 10, 2024 |
News
HRMY or ONC: Which Is the Better Value Stock Right Now?
HRMY,
ONC
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and BeiGene, Ltd. (ONC). But which of these two stocks is more attractive to value investors?
Read More
Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now
HRMY
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Harmony Biosciences (HRMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
About Harmony Biosciences Holdings, Inc. (HRMY)
- IPO Date 2020-08-19
- Website https://www.harmonybiosciences.com
- Industry Biotechnology
- CEO Jeffrey M. Dayno
- Employees 268
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.